Angiotensin-converting enzyme inhibitor in a human model of restenosis

Percutaneous transluminal coronary angioplasty (PTCA) was introduces by Andreas Gruentzig in 1977, as an alternative treatment for coronary artery bypass grafting (CABG) to restore coronary blood flow in patients with obstructive coronary artery disease (15). Increased experience and advances in technology have resulted in a high primary success rate (over 90%) and a low compilation rate (death, non-fatal myocardial infarction; 4–5%) (9). However, the late restenosis rate (17% to 40%) still limits the long-term benefit of the procedure (21, 23, 47, 52).